FDA Modernization: Opportunities for patient impact and economic development

Each new drug requires over 15 years and $2 billion to evolve from the earliest stages of research to ultimate approval for use in patients. New tools — including AI models for drug discovery, bioprinting of organoids, and organs-on-a-chip promise to reduce the cost and timeline, although they have not yet been integrated into the regulatory pathway for medical products. The FDA Modernization Act of 2022 opened the door to the use of cutting-edge platforms in clinical and nonclinical development, providing a generational opportunity for innovators and ecosystem builders alike. Join panelists as they discuss the patient impact and the economic development opportunities made possible thanks to FDA Modernization.

A reception and networking will follow.

Moderator

Griffin St Louis
Senior Program Manager, Maryland Innovation Initiative
TEDCO
 

Panelists

Colleen Heisey
Partner, Life Sciences
Jones Day

Robb Lawrence
Founder and President
Salient Consulting

Entrepreneur-in-Residence
University of Maryland, Baltimore

Paul Locke, DrPH, JD, MPH
Professor
Johns Hopkins Bloomberg School of Public Health

Sponsored by